Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 9/20 | 1.00 |
| ▸ | MBOAT4 | Q96T53 | 4/20 | 1.00 |
| ▸ | CCR6 | P51684 | 1/20 | 1.00 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.71 |
| ▸ | USP7 | Q93009 | 2/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.71 |
| ▸ | STAT3 | P40763 | 1/20 | 0.71 |
| ▸ | RORC | P51449 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27366480 | 1.00 | NOS2 (1.00) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL17553226 | 1.00 | NOS2 (1.00) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL91617 | 1.00 | NOS2 (1.00) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL7717245 | 1.00 | NOS2 (1.00) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL144428 | 1.00 | NOS2 (1.00) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL25972866 | 0.93 | NOS2 (0.86) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL3994632 | 0.88 | NOS2 (0.80) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL3994634 | 0.88 | NOS2 (0.80) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL20128433 | 0.88 | NOS2 (0.80) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL16526572 | 0.87 | NOS2 (0.77) | NOS2MBOAT4CCR6KEAP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746880-A2 | METHODS OF TREATING DILATED CARDIOMYOPATHY | Regencor, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3452041-B1 | COMPOSITIONS AND METHODS FOR ADMINISTERING PPAR-GAMMA-AGONISTS, SURFACTANT PEPTIDES AND PHOSPHOLIPIDS | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2026-01-14 | — | — | EP | claimed |
| EP-4580612-A1 | USE OF NRF2 ACTIVATORS FOR THE TREATMENT OF CEREBRAL SMALL VESSEL DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-07-09 | — | — | EP | claimed |
| US-20250073321-A1 | Modulation of Oxidative Stress and Amino Acid Metabolism for the Treatment or Prevention of Diseases and Disorders | UNIV NEW YORK (US) | 2025-03-06 | — | — | US | claimed |
| WO-2025024320-A2 | METHODS OF TREATING DILATED CARDIOMYOPATHY | REGENCOR, INC. (US) | 2025-01-30 | — | — | WO | claimed |
| CN-118903154-A | New use of compound CDDO-Im for preventing or treating foot-and-mouth disease | 中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心) | 2024-11-08 | — | — | CN | claimed |
| CN-118121610-A | Application of CDDO-Im in preparation of drugs for preventing or treating hepatic fibrosis | 西南交通大学 | 2024-06-04 | — | — | CN | claimed |
| EP-4373577-A1 | ACTRII PROTEINS AND USES THEREOF | Acceleron Pharma Inc. (US) | 2024-05-29 | — | — | EP | claimed |
| EP-4351626-A2 | ACTRII PROTEINS AND USES THEREOF | Acceleron Pharma Inc. (US) | 2024-04-17 | — | — | EP | claimed |
| EP-4351723-A2 | ACTRII PROTEINS AND USES THEREOF | Acceleron Pharma Inc. (US) | 2024-04-17 | — | — | EP | claimed |
| EP-4073101-A1 | SINGLE-ARM ACTRIIA AND ACTRIIB HETEROMULTIMERS AND METHODS FOR TREATING PULMONARY HYPERTENSION | Acceleron Pharma Inc. (US) | 2022-10-19 | — | — | EP | claimed |
| EP-4034168-A1 | METHODS FOR DEPLETION OF DELETERIOUS MITOCHONDRIAL GENOMES | University Of Massachusetts (US) | 2022-08-03 | — | — | EP | claimed |
| WO-2022150590-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION | ACCELERON PHARMA INC. (US) | 2022-07-14 | — | — | WO | claimed |
| CN-114591418-A | Threonine 166 th phosphorylation modification of PPAR gamma protein and application thereof | 南京大学 | 2022-06-07 | — | — | CN | claimed |
| US-20220160879-A1 | METHODS AND COMPOSITIONS FOR IRREVERSIBLE ENZVME INHIBITION | TRITERPENOID THERAPEUTICS, INC. | 2022-05-26 | — | — | US | claimed |
| US-20220096709-A1 | WOUND HEALING THERAPEUTIC HYDROGELS | UNIV NEW YORK (US) | 2022-03-31 | — | — | US | claimed |
| EP-3972986-A1 | METHODS AND COMPOSITIONS FOR IRREVERSIBLE ENZYME INHIBITION | Triterpenoid Therapeutics, Inc. (US) | 2022-03-30 | — | — | EP | claimed |
| US-10335420-B2 | Nanoparticle-based tumor-targeted drug delivery | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-07-02 | — | — | US | claimed |
| US-20180153898-A1 | COMPOSITIONS FOR MODULATING PD-1 SIGNAL TRANSDUCTION | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. | 2018-06-07 | — | — | US | claimed |
| US-20150133507-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | ARES TRADING S.A. (CH) | 2015-05-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133507-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | PPARG, PPARA, PPARD | NOS2 633/4885MBOAT4 916/4885CCR6 1416/4885 |
| US-10335420-B2 | Nanoparticle-based tumor-targeted drug delivery | LGMN, LAMP1, LNPEP | NOS2 4488/4885MBOAT4 2276/4885CCR6 3784/4885 |
| US-20220160879-A1 | METHODS AND COMPOSITIONS FOR IRREVERSIBLE ENZVME INHIBITION | LONP1, KEAP1, RCE1 | NOS2 4015/4885MBOAT4 2496/4885CCR6 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.